Introduction
Telomeres are the termini of eucaryotic chromosomes consisting of tandem repeats of 5 0 -TTAGGG-3 0 and proteins that bind to these repeat sequences (Moyzis et al., 1988; Muniyappa and Kironmai, 1998) . It ensures the complete replication of chromosome ends, impart protection to ends from nucleolytic degradation, end-toend fusion, and guide the localization of chromosomes within the nucleus (Muniyappa and Kironmai, 1998) . Recent studies have implicated key roles for telomeres in diverse cellular processes such as regulation of gene expression, cell division, cell senescence, and cancer (Pays, 1985; Greider, 1992; Allsopp et al., 1995; Vaziri and Benchimol, 1996; Muniyappa and Kironmai, 1998; Gilley et al., 2005) . A ribonucleoprotein complex, telomerase, is responsible for extending telomere ends and thus maintains telomere length (Greider and Blackburn, 1985; Morin, 1989) . The minimum core structure of telomerase can be reconstituted in vitro by an RNA subunit and the telomerase reverse transcriptase (TERT) (Weinrich et al., 1997; Beattie et al., 1998; Greenberg et al., 1998) . TERT adds on TTAGGG sequences onto chromosomal ends by using the intrinsic RNA component (TERC) as a template, thereby compensating for telomere loss that normally occurs with each cell division (Greider and Blackburn, 1985; Morin 1989) .
Telomerase activity is undetectable in most normal adult human somatic cells, but in B85% of human cancers and immortalized cell lines, telomerase becomes highly activated (Kim et al., 1994; Nakayama et al., 1998; Shay and Bacchetti, 1997; Liu, 1999) . In addition, telomerase is expressed in some normal rodent organs having self-renewal properties, such as the liver, spleen, thymus, and testis, even in adult animals (Greider, 1998) . This activity has also been found in activated lymphocytes, and more recently in injured and inflamed skin, fibrotic liver, hypertensive blood vessels, and injured lungs undergoing fibrosis (Tahara et al., 1995; Taylor et al., 1996; Tsujiuchi et al., 1998; Liu et al., 1999 Liu et al., , 2002 Nozaki et al., 2000) . Induction of this activity in injured tissues suggests a potential role for telomerase in the repair and/or fibrotic process. These findings also suggest that in normal adult tissues, telomerase is suppressed, but can be induced upon certain types of injury. However, the mechanism of how telomerase is suppressed or induced is far from clear, thus preventing further progress in understanding the role of telomerase in tissue injury, repair, and fibrosis.
Many lines of evidence indicate that telomerase is reversibly regulated. There is abundant evidence that the regulation of telomerase is multifactorial in mammalian cells, involving telomerase gene expression, post-translational protein-protein interactions, and protein phosphorylation (Li et al., 1998 (Li et al., , 1999 Cong et al., 1999; Holt et al., 1999; Kang et al., 1999; Wick et al., 1999) . Recent studies have found that de novo activation of human TERT (hTERT) gene transcription is the dominant, rate-limiting step in telomerase activation. Several proto-oncogenes and tumor suppressor genes have been implicated in the regulation of hTERT gene expression including c-myc, a proto-oncogene product that activates telomerase by direct binding to the E-boxes of the TERT promoter (Wang et al., 1998; Horikawa et al., 1999; Takakura et al., 1999; Wu et al., 1999) . Furthermore, in normal cells that are devoid of telomerase activity, constitutive expression of TERC is detectable, confirming that it is the induction of TERT gene expression that confers telomerase activity in these cells (Feng et al., 1995; Avilion et al., 1996) . This indicates that the key to understanding regulation of telomerase activity in cells primarily depends on elucidating the regulation of TERT gene expression. This is supported by the observation that transient induction of telomerase activity in fibroblasts isolated from bleomycin-injured lungs during the period of active fibrosis is paralleled by an increase in TERT mRNA (Nozaki et al., 2000; Liu et al., 2002) . The transient nature of this induction indicates some turn off mechanism that may be related to that which is responsible for suppressing telomerase in normal adult somatic cells. Interestingly in this regard, the induced activity in lung fibroblasts is repressed by treatment with transforming growth factor b (TGFb) via as yet unknown mechanisms (Liu et al., 2002) .
In this paper, the role of Smad3 in the inhibition of rat TERT (rTERT) gene transcription by TGFb was suggested by studies using fibroblasts with induced telomerase activity that were isolated from rat lungs with bleomycin-induced fibrosis. The results revealed that TGFb induced Smad3 expression and activation had two effects on the inhibition of the rTERT gene transcription. First, Smad3 inhibited the expression of cmyc, an activator of TERT gene expression, thus indirectly suppressing rTERT transcription. Second, Smad3 could bind to a Smad binding element (SBE) and thus directly suppress rTERT gene expression.
Results

TGFb inhibited rTERT gene transcription
Previously we reported transient induction of telomerase activity in fibroblasts isolated from bleomycin-injured lungs during the period of active fibrosis, which was suppressed by TGFb (Nozaki et al., 2000; Liu et al., 2002) . To begin uncovering the mechanism of this suppression by TGFb, an attempt was made to clone the rTERT promoter for use in studying transcriptional regulation of rTERT gene expression. Initially we BLASTed the rTERT cDNA sequence with the rat genome sequence and identified eight continuous homologous blocks between the rTERT cDNA and a single piece of rat genomic fragment which is B85 and B50% homologous to the published mouse and human TERT promoter, respectively (Figure 1) . It was then cloned by PCR amplification from the rat genome and fused with a luciferase reporter gene. The promoter activity was then tested in terms of the luciferase activity after transfection into fibroblasts isolated from bleomycin-injured rat lung. Consistent with the previous report of high induced telomerase activity in such fibroblasts (Nozaki et al., 2000; Liu et al., 2002) , the luciferase activity was high in these cells, which was indicative of active rTERT promoter activity and thus transcription (Figure 2) . Treatment of transfected cells with increasing doses of TGFb caused up to B60% inhibition of the expressed luciferase activity at the highest dose used (Figure 2a) . Analysis of the endogenous TERT mRNA levels showed similar dose-dependent inhibition by TGFb (Figure 2b ). Since the luciferase expression was under the control of TERT gene promoter, this finding suggested that TGFb controlled rTERT expression at the transcriptional level.
Effects of TGFb on Smad and c-myc expression
TGFb is known to signal via the Smad pathway using Smad2 and Smad3 as the receptor-regulated components, while Smad1 is identified as the effector for BMP signaling (Derynck and Zhang, 2003; Groneberg et al., 2004) . Smad1 has been reported as a repressor for hTERT gene transcription by competing for binding of c-myc (a cellular proto-oncogene that activates TERT gene expression) to the E-box in the hTERT gene promoter (Oh et al., 2000) . Although TGFb is not known to signal through Smad1, in view of this previous report of Smad1 in repressing the hTERT gene, the level of Smad1 expression in rat lung fibroblasts from bleomycin-injured lung was also examined in this initial screen for Smad components. To determine if these components and c-myc might be involved in TGFb repression of rTERT expression, the levels of Smad1, Smad2, Smad3, and c-myc proteins were analysed by Western blotting. The results showed low but detectable levels of Smad1 in these cells, which were not significantly affected by treatment with increasing doses (2-25 ng/ml) of TGFb (Figure 3 ). Smad2 was also detectable and not significantly altered by TGFb treatment. However, Smad3 levels were increased in response to TGFb treatment, and which was accompanied by a dose-dependent decrease in c-myc protein expression. The loading control protein, b-tubulin, was unaffected by the treatments. These findings suggested potential roles for Smad3, perhaps in conjunction with c-myc, in TGFb repression of rTERT gene expression.
Smad3 inhibited rTERT gene transcription
In view of the elevated Smad3 level associated with TGFb-induced repression of rTERT, the effect of Smad3 overexpression on rTERT promoter activity was examined. Constitutive sense or antisense Smad3 expression constructs were made and used to overexpress or inhibit Smad3 expression, respectively. Rat lung fibroblasts from fibrotic lungs were transfected with the rTERT promoter construct and then cotransfected with the indicated sense or antisense Smad3 construct. Cotransfection with the sense Smad3 construct signifi- Fibroblasts isolated from bleomycin-injured lungs were transfected with the rTERT promoter construct (pGL3-tertp-luc, also abbreviated as rtertp-luc). The cells were then treated with buffer only or the indicated dose of TGFb. After 48 h, cell extracts were harvested and assayed for luciferase activities. The luciferase activity for each sample was normalized to its respective Renilla luciferase control activity and shown as means7s.e. of triplicate samples. Inhibition by TGFb was statistically significant (Po0.05) at all doses tested. (b) Rat fibroblasts as in (a) were treated with buffer only or the indicated dose of TGFb for 6 h. Total RNA was then extracted and assayed for TERT mRNA level by real-time PCR. Results were expressed as 2 ÀDDCT using GAPDH as the internal control and untreated cell samples as calibrator. Means7s.e. of triplicate samples are shown. All mean values in the TGFb-treated groups were statistically different (Po0.05) from the control (buffer only treated) group. Effects of Smad3 on rTERT promoter activity. Rat fibroblasts isolated from bleomycin-injured lung were transfected with the rTERT promoter construct (pGL3-tertp-luc), and either a constitutively Smad3 expression construct (pEGFP-Smad3), an antisense smad3 expression construct (pEGFP-Smad3-REV), or expression vector only (pEGFP-C2). Cells were then treated with buffer only (None) or with 2 ng/ml TGFb (TGFb). Cell extracts were then harvested and assayed for luciferase activities, which were normalized to their respective Renilla luciferase control activity and shown as means7s.e. of triplicate samples. The inhibitory effects of TGFb were statistically significant in all cells cotransfected with the indicated plasmid. Compared to control cells (transfected with empty vector), the pEGFP-Smad3 cotransfected cells showed significantly reduced promoter activity, but not in TGFb-treated cells. All activities in the pEGFP-Smad3-REV cotransfected cells were significantly elevated compared to the pEGFP-Smad3 or pEGFP-C2-treated cells with or without TGFb treatment. All statistical analysis was by ANOVA plus Scheffe´'s test with Po0.05 indicative of significance.
Inhibition of rat TERT gene transcription by TGFb B Hu et al further decreased by the sense Smad3 plasmid. No significant effect was noted on the protein loading control, b-tubulin. Since c-myc is a known activator of TERT gene expression (Wang et al., 1998; Wu et al., 1999; Oh et al., 2000) , the inhibition of c-myc by Smad3 suggests a mechanism by which TGFb could inhibit rTERT gene expression.
Smad3 regulation of the rTERT promoter
Although TGFb could presumably inhibit rTERT gene expression by suppressing expression of the rTERT promoter activator, c-myc, analysis of the rTERT promoter also revealed the existence of an SBE upstream of the E-boxes to which c-myc would presumably bind ( Figure 1 ). Thus, direct Smad3 binding to this SBE could also directly inhibit the rTERT promoter, without mediation by reduction in c-myc expression. To test this possibility, the effects of mutating the E-boxes or SBE ( Figure 6a ) on promoter activity and its responsiveness to TGFb treatment were examined. Consistent with the activator function of c-myc, mutation of the E-boxes caused a marked reduction (>70% inhibition) in rTERT promoter activity relative to that in the wildtype promoter construct ( Figure 6b ). In contrast, the SBE mutant promoter showed significantly greater activity relative to the wild-type promoter, while a control mutant construct (mutated at an irrelevant site) was not significantly different from the wild-type promoter. When the cells were treated with TGFb, the expected reduction (45% inhibition) in wild-type promoter activity was observed, and interestingly the level of TGFb-induced inhibition was comparable (51% inhibition) in the E-box mutated construct. In addition, Smad3 overexpression using the Smad3 expressing plasmid further inhibited rTERT promoter activity by >30%, relative to cotransfection with the empty vector (data not shown). In contrast to the findings using the E-box mutated construct, the level of TGFb-induced inhibition was significantly reduced (27% inhibition) in the SBE-mutated construct (Figure 6b ). These findings indicated that while constitutive rTERT promoter activity was inhibited by mutation of the E-boxes, the inhibitory effect of TGFb on promoter activity remained intact. However, mutation of the SBE impaired the inhibitory response to TGFb, suggesting the ability of Smad3 to bind directly to this element in downregulation of rTERT gene expression by this cytokine.
Smad3 binding to the SBE Smad3 is reported to recognize and bind 'CAGA' containing elements to regulate gene transcription (Dennler et al., 1998; Zawel et al., 1998) . Scanning of the rTERT promoter revealed existence of such an SBE containing two 'CAGA' elements and located at À748 to À729 from the transcriptional start site (TSS), which is conserved in both mouse and human TERT promoters ( Figure 1 ). To confirm that Smad3 binds this SBE found in the rTERT promoter, electrophoretic mobility shift assay (EMSA) was undertaken using a doublestranded oligonucleotide probe with sequence corresponding to À761 to À715 from the TSS of the rTERT promoter. As shown in Figure 7 , a major retarded band was formed when pure Smad3 was incubated with the probe, indicative of complex formation. Competition with 100-fold excess of cold probe abolished this major band, thus indicating specificity of the binding. A minor band was also noted but was not affected by competition with cold probe, indicating a nonspecifically bound complex. The major band was super-shifted when the Smad3 was preincubated with specific anti-Smad3 antibody but not with nonspecific IgG control, while the minor band was unaffected by either preincubation. Similar findings were noted when nuclear extracts from TGFb-treated cells were analysed instead of pure Smad3 (data not shown). No retarded bands were noted in the absence of Smad3 or nuclear extract (Figure 7 ), or when an oligonucleotide probe with a mutated SBE sequence was used as the hot probe (data not shown). Thus in conjunction with being functionally active (Figure 6b ), the Smad3 binds to the SBE in the rTERT promoter.
To further confirm that Smad3 binds to the SBE in the rTERT promoter in intact cells treated with TGFb, a chromatin immunoprecipitation assay (ChIP assay) was performed. The results showed that an approximately 400 bp DNA fragment was amplified by primers spanning the rTERT promoter SBE flanking region when an anti-Smad3 antibody precipitated DNA was used as template ( Figure 8 ). As expected, the same 400 bp DNA fragment was amplified when the supernatant of the cell lysate (input DNA) or rat genomic DNA (genomic DNA) was used as template in the PCR analysis. Samples incubated with nonimmune rabbit IgG or buffer (phosphate-buffered saline (PBS)) only for precipitation of DNA, failed to yield a product upon amplification using the same primers. Thus, the amplified fragment was specifically precipitated by the anti-Smad3 antibody, indicating that Smad3 did bind to the SBE in the rTERT promoter in the intact cell. Figure 4) or empty vector only (pEGFP-C2) were transfected into rat fibroblasts isolated from bleomycin-injured lung. The cells were treated with buffer only (None) or with TGFb (2 ng/ml). They were then lysed and the cell extracts analysed by Western blotting for c-myc protein expression. Equal amounts of protein were loaded for gel electrophoresis prior to blotting. A representative blot is shown.
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Discussion
Telomere shortening limits the proliferative capacity of primary human cells and restrains the regenerative capacity of organ systems during chronic diseases and aging (Djojosubroto et al., 2003; Satyanarayana et al., 2004) . Telomere shortening apparently has a dual role in tumor development and progression. On the one hand, it induces chromosomal instability and the initiation of cancer; on the other hand, tumor progression requires stabilization of telomeres (Satyanarayana et al., 2004) . The predominant mechanism of telomere stabilization in tumor cells is the expression of the telomeresynthesizing enzyme, telomerase (Satyanarayana et al., 2004) . Therefore, understanding of the regulatory mechanism of telomerase should be instructive in assessing the role of its induction in certain disease states, and evaluating novel therapeutic approaches for both cancer and regenerative disorders such as fibrosis.
Previous studies indicate that the regulation of telomerase is multifactorial in mammalian cells, involving telomerase gene expression, post-translational protein-protein interactions, and protein phosphorylation (Li et al., 1998 (Li et al., , 1999 Cong et al., 1999; Holt et al., 1999; Kang et al., 1999; Wick et al., 1999) . However, the de novo activation of hTERT gene transcription appears to be the dominant, rate-limiting step in telomerase activation (Takakura et al., 1999) ; thus understanding how it is regulated should be instrumental in understanding its role in normal development, cancer, and Figure 6 Effects of mutations on rTERT promoter activity. In the upper panel (a) is a cartoon depicting the wild-type promoter construct and the sites of mutations for the various constructs. The relative locations from the transcription start site (bent arrow) of the SBE (oval), E-boxes (rectangle) and the irrelevant mutant control site (solid triangle) were as indicated in the wild-type construct (rtertp-Luc). The E-box (rtert-Luc-Em) and SBE (rtert-Luc-SBEm) mutant constructs were indicated with absent E-boxes or SBE, respectively. These constructs and the control irrelevant mutant (rtertp-Luc-Control) and empty (pGL3-basic) plasmids were transfected into rat fibroblasts isolated from bleomycin-injured lung as indicated in the lower panel (b). Cell extracts were then harvested and assayed for luciferase activities. The luciferase activity was normalized for each construct to its respective Renilla luciferase control activity and shown as means7s.e. of triplicate samples. The E-box mutant promoter had significantly diminished activity compared to the wild type, SBE mutant, or control (rtertp-Luc-Control) constructs in both untreated and TGFb-treated cells. The inhibitory effects of TGFb treatment were significant in all transfected cells, except for the empty vector, which had only background activity, and the SBE mutant construct. The activity of the control mutant promoter construct (rtertp-Luc-Control) was not significantly different from that of the wild-type promoter. All tests were by ANOVA plus Scheffe´'s test, with Po0.05 indicative of significance. (Devereux et al., 1999; Dessain et al., 2000) . However, there is incomplete agreement in the published findings, thus Sp1 is known as a repressor but has also been reported to cooperate with c-myc in activation of hTERT expression . It is also suggested that the inhibition by WT1 and MZF2 may be cell specific or of minor importance (Cong et al., 2002) . Previously, we found that TGFb inhibits the induced TERT gene expression in fibroblasts isolated from injured/fibrotic lungs, but the mechanism is undetermined (Liu et al., 2002) . Other studies have also suggested the ability of TGFb to inhibit TERT expression in cancerous cells without clarifying the underlying mechanism (Yang et al., 2001; Zhao et al., 2003) . Since inhibition of the induced telomerase activity is potentially an important objective in cancer therapy with potential relevance to treatment of chronic fibrotic diseases, we investigated the possible mechanism by which TGFb could inhibit TERT gene expression. With this objective in mind, we first identified the rat TERT gene promoter based on the rat genomic sequence and the known murine promoter sequence, and cloned it by PCR amplification. Analysis of the promoter sequence indicated the presence of two Eboxes, which are known to bind c-myc, as well as an SBE. After fusion with a luciferase reporter gene, the activity of this rTERT promoter construct was used in studies to evaluate how this promoter was regulated by TGFb. Initial analysis confirmed that TGFb inhibited induced telomerase expression in fibroblasts isolated from bleomycin-injured rat lung and that the inhibition was at the transcriptional level as revealed by the rTERT promoter construct studies. Since TGFb is known to signal commonly via the Smad pathway and c-myc is known to be involved in regulation of TERT transcription (Wang et al., 1998; Wu et al., 1999; Kyo et al., 2000; Xu et al., 2001; Derynck and Zhang, 2003; Groneberg et al., 2004) , we initially analysed expression of these proteins. While Smad1 is not utilized in TGFb signaling, a previous report indicates that this Smad component utilized by BMP signaling may be involved in inhibition of TERT gene expression (Oh et al., 2000) . We therefore confirmed that several key Smad components, including Smad1 and c-myc, were detectably expressed in these telomerase expressing cells. However, no significant effects on Smad1 and Smad2 expression were detectable in response to TGFb treatment. Moreover, when they were treated with TGFb, Smad3 expression was increased while c-myc expression was concomitantly decreased in a dose-dependent manner. Thus, increased TGFb signaling via Smad3 appears to be correlated with decreased c-myc and telomerase expression. These Figure 8 ChIP analysis of Smad3 binding to the SBE in the rTERT promoter. Formaldehyde crosslinked chromatin samples from TGFb-treated cells were incubated with anti-Smad3 antibody (Anti-Smad3), nonimmune rabbit IgG (Rabbit IgG), or PBS as indicated. These precipitated DNA samples, along with untreated whole samples (Input DNA) and rat genomic DNA (Genomic DNA) controls were analysed by PCR using primers spanning the SBE 400 bp region of the rTERT promoter. The PCR products and a 100 bp DNA ladder were analysed by electrophoresis on 1% agarose gel.
Inhibition of rat TERT gene transcription by TGFb
Inhibition of rat TERT gene transcription by TGFb B Hu et al findings would be consistent with previous studies showing the importance of c-myc in upregulation of TERT gene expression, and suggest that TGFb induced Smad signaling may be responsible for the observed suppression of c-myc expression and consequent repression of rTERT transcription. This possibility is supported by recent evidence that c-myc transcription is repressed by TGFb via a repressive SBE in the c-myc promoter (Frederick et al., 2004) .
However, the presence of an SBE in the rTERT promoter suggested a potential additional mechanism for direct inhibition of transcription by Smad3. To evaluate this possibility, we evaluated the effects of Smad3 overexpression and suppression of its constitutive and TGFb-induced expression on rTERT promoter activity. Smad3 overexpression by transfection with a Smad3 expression plasmid significantly inhibited the constitutively high rTERT promoter activity in these telomerase expressing lung fibroblasts, while suppression of endogenous Smad3 expression with an antisense Smad3 plasmid stimulated promoter activity. A similar pattern of inhibition and stimulation by these respective plasmids was also observed in TGFb-treated cells. Interestingly, the antisense plasmid essentially completely abolished the inhibitory effect of TGFb on rTERT promoter activity. However, while documenting the regulatory effects of Smad3 on rTERT promoter activity, these findings were not sufficient to prove a direct repressive effect of Smad3 on the promoter. Furthermore, examination of the effects of these Smad3 plasmids on c-myc expression confirmed a recent study (Frederick et al., 2004) that Smad3 was indeed repressive for c-myc expression. This repressive effect was found to be additive to that due to TGFb treatment. In an effort to distinguish indirect (e.g. via c-myc) vs direct effects of Smad3 in regulating the rTERT promoter, two mutant promoter constructs were made to examine the impact of mutations in the SBE or E-boxes on promoter activity. Consistent with the importance of c-myc as previously suggested (Wang et al., 1998; Wu et al., 1999; Kyo et al., 2000; Xu et al., 2001) , mutation of the E-boxes caused a profound loss in constitutive and TGFb-stimulated promoter activity. However, TGFb treatment still caused a similar level of inhibition as in cells transfected with the wild-type promoter. Thus, despite the lower level of promoter activity in the E-box mutant promoter, it was still able to fully respond to TGFb treatment as manifested by the essentially equal level of inhibition in activity. This would indicate the existence of an additional mechanism of TGFb repression of rTERT transcription that is independent of c-myc acting on the E-boxes in the promoter.
Given the presence of an SBE in the rTERT promoter, an obvious possibility for a c-myc independent mechanism is that Smad3 could bind directly to this element and effect direct repression of rTERT transcription. Indeed, when the SBE was mutated in this rTERT promoter construct, its activity was enhanced compared to that of the wild-type promoter, with or without TGFb treatment. These findings suggested that Smad3 could indeed directly repress promoter activity. While the suppressive effect of TGFb on promoter activity was significantly reduced in the SBE mutant promoter, it was not completely eliminated, indicative perhaps of the alternate indirect inhibitory pathway via c-myc that should remain intact in these cells. Actual binding of Smad3 to the SBE sequence in the rTERT promoter was confirmed by EMSA analysis and ChIP assay.
In summary, we have analysed regulation of the rTERT promoter based on the importance TGFb in regulating the induced telomerase expression in fibroblasts isolated from remodeling or fibrotic lungs in response to injury. Based on the findings, evidence was presented to document the existence of at least two mechanisms by which TGFb could effect repression of rTERT gene expression. First an indirect mechanism is suggested by which TGFb-induced Smad3 inhibits cmyc expression and thus reduce its activating effect via the E-boxes in the rTERT promoter. A second direct mechanism is suggested by the presence of an SBE in this promoter that could bind Smad3 and whose mutation resulted in greater promoter activity. Studies with the mutant promoters also suggest that c-myc regulation may be important for constitutive rTERT expression, but that the response to TGFb-induced repression may be more dependent on direct repressive effects of Smad3 on the promoter via binding to the SBE.
Material and methods
Animal models and cell culture Female-specific pathogen-free Fisher 344 rats (7-8 weeks old) were purchased from Charles River Breeding Laboratories, Inc. (Wilmington, MA, USA). Pulmonary fibrosis was induced by the endotracheal injection of 7.5 U/kg body weight of BLM (Blenoxane; Mead Johnson, NJ, USA) in sterile PBS as before (Nozaki et al., 2000; Liu et al., 2002) . The control group received the same volume of sterile PBS only. At 2 weeks after BLM injection, the rats were killed and fibroblasts were isolated from the lungs as described previously (Phan et al., 1985) . The cells were cultured in DMEM supplemented with 10% plasma-derived serum (PDS) (Cocalico Biologicals, Inc., Reamstown, PA, USA), 100 U/ml penicillin, 100 mg/ml streptomycin, 0.25 mg/ml fungizone, 1% ITS (insulin, transferrin, selenium) (Sigma Chemicals, St Louis, MO, USA), 5 ng/ml PDGF (R&D Systems, Minneapolis, MN, USA) and 10 ng/ml EGF (R&D Systems, Minneapolis, MN, USA).
TGFb treatment
Cells were cultured overnight in complete medium. They were deprived of growth factors by rinsing twice in PBS and incubating in DMEM containing 0.5% PDS for 24 h. This was followed by treatment with the indicated concentrations of TGFb 1 (R&D Systems, Minneapolis, MN, USA) for 48 h before harvesting for analysis as indicated below.
Plasmid and constructs
To clone the promoter, the rTERT gene sequence (XM_229474) was BLASTed with the published rat genome sequence. Eight continuous homologous blocks were found (Figure 1 ). It was sent to GenBank as sequence DQ021473. Based on this deduced promoter sequence, an oligonucleotide primer corresponding to the sense strand of the DNA from þ 165 to þ 183 from the TSS with sequence 5 0 -GCACGCA CACTAGGCACTG-3 0 , and a primer corresponding to the sense strand of the DNA from À1121 to À1101 with sequence 5 0 -CCATGCCCAGCTATATTCTTG-3 0 were designed to amplify the rTERT promoter from the genome by PCR. The resulting fragment was then confirmed by DNA sequencing and inserted into promoterless vector pGL3-Basic to form plasmid pGL3-rtertp-luc wherein luciferase expression was driven by the rTERT promoter. It was used as a template to generate rTERT promoter constructs with mutated E-Boxes (pGL3-rtertp-luc-Em) or SBE (pGL3-rtertp-luc-SBEm) using the QuickChange mutagenesis protocol (Stratagene, La Jolla, CA, USA). The following primer pairs were used for generation of the E-Box mutated promoter (corresponding to DNA sequence of rTERT promoter at À650 to À624 and þ 68 to þ 97 from the transcriptional start site, respectively):
For generation of the SBE-mutated promoter, the following primer pairs were used (corresponding to sequence À761 to À715 from transcriptional start site in the rTERT promoter):
Constitutively Smad3 expression plasmid pEGFPC2-Smad3 was a gift from Dr Wylie Vale, Salk Institute, and from which an antisense Smad3 expression plasmid pEGFPC2-Smad3-Rev was made as previously described (Hu et al., 2003) .
To make the GST-Smad3 fusion protein expression plasmid, the Smad3 coding region was cut from the plasmid pEGFPC2-Smad3 and inserted into vector pGEX-4T-1 in codon to form plasmid pGEX4T-Smad3.
mRNA analysis by real-time PCR For mRNA analysis, fibroblasts isolated from bleomycininjured lung tissue were treated with the indicated doses of TGFb for 6 h. Total RNA was then isolated and used for realtime PCR analysis for assessment of rTERT mRNA levels. The primer sequences were as follows: forward primer, 5 0 -GTGGAGGTTGTTGCCAATATGAT-3 0 ; reverse primer, 5 0 -CCACTGCATACTGGCGGATAC-3 0 ; and probe, 5 0 -6FAM-ACTCGGAGAGCACGTACMGBNFQ-3 0 . Primers and probe for the reference gene, GAPDH, were purchased from Applied Biosystems (PE/ABI, Foster City, CA, USA). For each assay, 200 ng of total RNA was used as template. One-step real-time PCR (481C for 30 min, 951C for 10 s followed by 50 cycles of 951C for 10 s, 601C for 1 min) was undertaken with the Taqman One Step RT-PCR Master Mix (PE/ABI) using a GeneAmp 5700 Sequence Detection System (PE/ABI). Results were expressed as 2 ÀDDCT using GAPDH as the reference or internal control, and untreated cell samples as the calibrator.
Purification of Smad3 and nuclear extract preparation Escherichia coli strain BL21 hosting the GST-Smad3 expression plasmid pGEX4T-Smad3 was cultured overnight and induced by IPTG for 3 h at room temperature for the expression of GST-Smad3. It was collected and lysed in PBS. Smad3 was then purified to one band using bulk GST purification module (Amersham Biosciences) according to the manufacturer's instructions. It was then used in EMSA.
Nuclear extracts were prepared from untreated and TGFbtreated cultures as previously described (Hu et al., 2003 (Hu et al., , 2004 . Briefly, the cultures were rinsed twice with cold PBS, and then with Dignam's Buffer A (10 mM HEPES, pH 7.9, 10 mM KCl, 0.1 mM EDTA, 1 mM DTT, 0.5 mM phenylmethylsulfonyl fluoride (PMSF), and 4 mg/ml leupeptin). The cells were then scraped into Buffer A and washed once with the same. The cell pellet was finally resuspended in Buffer A and kept on ice for 15 min before brief extraction in 0.6% NP40. The extract was vortexed, centrifuged briefly and the cytoplasmic extract was then removed. The nuclei were further extracted in Dignam's Buffer C (20 mM HEPES, 1.5 mM MgCl 2 , 420 mM NaCl, 0.2 mM EDTA, 25% glycerol, 1 mM DTT, 0.5 mM PMSF, 4 mg/ml leupeptin) for 20 min on ice. The extracts were then centrifuged, and the supernatants stored at À701C until used. Protein concentration was determined using the BCA Assay (Pierce, Rockford, IL, USA).
Immunoblotting
All antibodies were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA), except for the anti-Smad3 antibody which was from Upstate USA, Inc. Cells (7 Â 10 4 / well) were plated in six-well plates and treated as above with TGFb. They were harvested by scraping into Laemmli's sample loading buffer. Equal amounts of protein were electrophoresed through 12% SDS polyacrylamide gels. The separated protein bands were transferred onto nitrocellulose membranes. Nonspecific binding was blocked with 10% nonfat milk (Bio-Rad Laboratories, Hercules, CA, USA) in 10 mM Tris-buffered saline containing 0.5% Tween 20 (TBST). After incubation with the indicated specific primary antibodies and corresponding HRP-conjugated secondary antibodies, respectively, the membranes were soaked in chemiluminescent substrate LumiGLO (New England Biolabs, Beverly, MA, USA) for 1 min and were exposed to Hyperfilm ECL film (Amersham Biosciences Co., Piscataway, NJ, USA).
Transfection and reporter gene assay All transient transfections were performed using the FuGENEt6 reagent (Roche Applied Science, Indianapolis, IN, USA) according to the manufacturer's instructions. Supercoiled DNA was isolated with an endotoxin-free Qiagen column kit (Qiagen Inc., Valencia, CA, USA). Unless otherwise indicated, cells were seeded in six-well plates at a density of 10 5 per well in DMEM containing 10% PDS, and incubated at 371C overnight. In all, 2 mg DNA of the construct of interest and 1 mg plasmid pRL-TK control vector (used for normalization) were cotransfected per culture in DMEM containing 0.5% PDS with or without 2 ng/ml TGFb treatment. To test the effect of Smad3 on TERT gene promoter, 2 mg pEGFP-Smad3, pEGFP-Smad3-Rev, or the expression vector pEGFP-C2 were also cotransfected with the luciferase constructs respectively. After 48 h, the cells were harvested, and the activity of firefly or Renilla luciferase was measured using the dual luciferase assay system from Promega Corporation (Madison, WI, USA). The relative luciferase activity was calculated by normalizing firefly luciferase activity to that of Renilla luciferase. Experiments with each construct were repeated 2-4 times and the relative activity was expressed as mean7s.e.
Electrophoretic mobility shift assay EMSA was conducted as previously described (Hu et al., 2003 (Hu et al., , 2004 . Double-stranded oligonucleotides containing the SBE site corresponding to the region between À761 and À715 from the transcriptional start site of the rat TERT promoter with the following sense strand sequence 5 0 -ACTGTGGAGACCACA GATTCCCTTTTTCCCAGAGATTCAAATTTCAG-3 0 was synthesized as a probe to detect the binding of Smad3 to the TERT promoter. Another set of primers in which the SBE was mutated to the sense sequence 5 0 -ACTGTGGAGACCAATT GTTCCCTTTTTCCCGGGGATTCAAATTTCAG-3 was also prepared to confirm the specificity of binding. They were labeled with 32 P and applied to EMSA reaction mixtures containing 1-3 mg of protein extract, 1.0 mg of Poly dI-dC, and 0.1 mg poly-L-lysine in a final volume 15 ml. Where indicated, the EMSA reaction mixtures were preincubated with the indicated antibodies on ice for 30 min prior to probe addition and incubation for another 20 min at room temperature. Samples were then analysed by electrophoresis on 4% nondenaturing polyacrylamide gels at 100 V in 1 Â TBE. Following electrophoresis, the gels were dried and exposed to X-ray film for 24 h.
ChIP assay
This was performed using a kit from Upstate-Cell Signaling Solutions (Charlottesville, VA, USA), using the manufacturer's protocol. Briefly, lung fibroblasts from bleomycininjured lungs were treated with TGFb for 24 h. After fixation with 1% formaldehyde in DMEM to crosslink bound transcription factors to DNA, the samples were then washed twice with PBS and then suspended in SDS lysis buffer. After sonication to shear the DNA to an average of 1000 base pairs, the lysates were centrifuged and the supernatants collected. After preclearing with protein A agarose, 20 ml of each sample was aliquoted separately for use as 'input DNA' in PCR analysis. The remainder of each sample was then divided equally into three aliquots for incubation with (1) anti-Smad3 antibody (anti-Smad3 bound DNA fraction), (2) nonimmune rabbit IgG (nonspecific antibody background DNA fraction), or (3) PBS-buffer (no antibody background fraction), respectively. Any immune complexes formed were affinity-adsorbed with protein A agarose and collected by centrifugation. The bound DNA was washed extensively and eluted from the protein A agarose with freshly made elution buffer (1% SDS, 0.1 M NaHCO 3 ). The eluates and the original 'input DNA' sample were incubated at 651C for 4 h to reverse the crosslink and then used as templates for PCR analysis along with the oligonucleotide primers A (5 0 -TCTCAAACATACCCCTG-3 0 ) and B (5 0 -CCAAAGCAGTGACCCTA-3 0 ) corresponding to À985 to À969 and À602 to À585 from the transcriptional start site in the rTERT promoter, respectively. These primers were designed to amplify a 400 bp rTERT promoter region containing the putative Smad3 binding element. The PCR products were then analysed by gel electrophoresis in 1% agarose, along with 100 bp DNA ladder from New England Biolabs Inc. (Ipswich, MA, USA).
Abbreviations rTERT, rat telomerase reverse transcriptase; BLAST, Basic Local Alignment Search Tool (National Center for Biotechnology Information software); EMSA, electrophoretic mobility shift assay; PBS, phosphate-buffered saline; PDS, plasmaderived serum; PMSF, phenylmethylsulfonyl fluoride; TGFb, transforming growth factor b.
